LENSAR is expected to report Q3 2026 revenue of $14.30 million and an EPS loss of $0.10, with the current stock price of $5.84 trading well below the $11.33 analyst target.

The central focus for investors is the adoption trajectory of the ALLY Adaptive Cataract Treatment System and its effect on high-margin procedure volumes. Despite seasonal procedure weakness typically expected in the third quarter, shareholders are looking for growth in recurring revenue, which recently accounted for 83% of total sales.

The company is coming off a profitable second quarter characterized by record adjusted EBITDA and a backlog of 13 system installations. Updates on international expansion and surgeon utilization rates will be critical for maintaining the stock's recent momentum.